A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects

NCT01291602 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Male and Female Japanese Volunteers

Interventions

DRUG: NXL104
DRUG: CAZ104
DRUG: Placebo

Sponsor

Pfizer